Literature DB >> 10435684

Determination of the etiological organism during acute exacerbations of COPD and efficacy of azithromycin, ampicillin-sulbactam, ciprofloxacin and cefaclor. Turkish Thoracic Society COPD Working Group.

S Umut1, B Tutluoglu, G Aydin Tosun, B Müsellim, M Erk, N Yildirim, H Vahapoglu, N Yilmaz, O Arseven, H Türker, M Erelel, A Ilvan, V Göylüsün, T Yilmaz Kuyucu, F Koşar, F Soysal, A Gür, S Unutmaz, S Oztürk, M Akman.   

Abstract

Acute exacerbations, most of which are due to lower respiratory tract infections, cause great morbidity and mortality in patients with chronic obstructive pulmonary disease (COPD) and most of these are due to lower respiratory tract infections. The aim of this study was to determine the causative organism and the effects of azithromycin, ampicillin sulbactam (sultamicillin), ciprofloxacin and cefaclor monohydrate therapy in COPD. One hundred and six patients with COPD in acute exacerbation were randomized into four groups for empiric antibiotic treatment following lung function tests and sputum examination. The most common strains isolated from sputum were Haemophilus influenzae (30.8%), Streptoccocus pneumoniae (12%) and Moraxella catarrhalis (7.7%). Azithromycin, sultamicillin, ciprofloxacin and cefaclor monohydrate were found to be effective in treating COPD exacerbations.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435684     DOI: 10.1179/joc.1999.11.3.211

Source DB:  PubMed          Journal:  J Chemother        ISSN: 1120-009X            Impact factor:   1.714


  2 in total

1.  Antibiotics for treatment of acute exacerbation of chronic obstructive pulmonary disease: a network meta-analysis.

Authors:  Hai-Lin Zhang; Min Tan; Ai-Min Qiu; Zhang Tao; Chang-Hui Wang
Journal:  BMC Pulm Med       Date:  2017-12-12       Impact factor: 3.317

2.  Azithromycin Versus Beta-lactams in Hospitalized Patients with Acute Exacerbations of COPD.

Authors:  Nour Baalbaki; Christopher Giuliano; Carrie L Hartner; Pramodini Kale-Pradhan; Leonard Johnson
Journal:  J Gen Intern Med       Date:  2022-03-22       Impact factor: 5.128

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.